Dose Intensity and Hematologic Toxicity in Older Breast Cancer Patients Receiving Systemic Chemotherapy
Dose Intensity and Hematologic Toxicity in Older Breast Cancer Patients Receiving Systemic Chemotherapy
复制标题
DOI：
10.1002/cncr.24560
复制
发表时间：
2009-11-15
期刊：
影响因子：
6.2
通讯作者：
Lyman, Gary H.
中科院分区：
文献类型：
--
作者：
Shayne, Michelle;Culakova, Eva;Lyman, Gary H.
背景技术背景：本前瞻性研究评价了在社区环境中接受根治性治疗的老年乳腺癌患者中导致血液学毒性的患者和治疗特征。方法：收集了1224例I期至III期乳腺癌患者的数据，其中207例年龄≥ 65岁（根据美国癌症联合委员会分期系统确定分级）。主要结局指标包括贫血、血小板减少、严重中性粒细胞减少、发热性中性粒细胞减少以及计划和实际相对剂量强度（RDI）。根据单变量和多变量logistic回归分析比较老年和年轻患者的血液学毒性和RDI降低。结果：老年患者的血小板减少并发症发生率（45.1%）与年轻患者（43.7%）无显著差异。贫血或血小板减少症的发生率也没有显著差异。约34.0%的老年患者接受RDI
BACKGROUND: This prospective study evaluated patient and treatment characteristics that contributed to hematologic toxicity in older breast cancer patients treated with curative intent in the community setting. METHODS: Data were collected on 1224 patients with stage I through III breast cancer, of whom 207 were aged >= 65 years (grading determined according to the American Joint Committee on Cancer staging system). Primary outcome measures included anemia, thrombocytopenia, severe neutropenia, febrile neutropenia, and both planned and actual relative dose intensity (RDI). Comparisons between older and younger patients regarding hematologic toxicity and reductions in RDI were based on univariate and multivariate logistic regression analyses. RESULTS: The neutropenic complication rate in older patients (45.1%) was not significantly different from that in the younger patients (43.7%). There were also no significant differences in rates of anemia or thrombocytopenia. Approximately 34.0% of the older patients received RDI